- Home
- MYGN vs SWI Comparison
MYGN vs SWI Comparison
Compare MYGN & SWI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- SWI
- Stock Information
- Founded
- MYGN 1991
- SWI 1999
- Country
- MYGN United States
- SWI United States
- Employees
- MYGN N/A
- SWI N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SWI Computer Software: Prepackaged Software
- Sector
- MYGN Health Care
- SWI Technology
- Exchange
- MYGN Nasdaq
- SWI Nasdaq
- Market Cap
- MYGN 2.0B
- SWI 2.5B
- IPO Year
- MYGN 1995
- SWI 2009
- Fundamental
- Price
- MYGN $13.36
- SWI $14.45
- Analyst Decision
- MYGN Hold
- SWI Hold
- Analyst Count
- MYGN 12
- SWI 7
- Target Price
- MYGN $23.92
- SWI $14.71
- AVG Volume (30 Days)
- MYGN 942.4K
- SWI 637.2K
- Earning Date
- MYGN 11-07-2024
- SWI 02-06-2025
- Dividend Yield
- MYGN N/A
- SWI N/A
- EPS Growth
- MYGN N/A
- SWI N/A
- EPS
- MYGN N/A
- SWI 0.22
- Revenue
- MYGN $823,600,000.00
- SWI $784,725,000.00
- Revenue This Year
- MYGN $13.82
- SWI $5.08
- Revenue Next Year
- MYGN $4.59
- SWI $3.04
- P/E Ratio
- MYGN N/A
- SWI $64.94
- Revenue Growth
- MYGN 12.15
- SWI 4.96
- 52 Week Low
- MYGN $12.87
- SWI $10.14
- 52 Week High
- MYGN $29.30
- SWI $14.94
- Technical
- Relative Strength Index (RSI)
- MYGN 26.22
- SWI 58.03
- Support Level
- MYGN $12.87
- SWI $13.76
- Resistance Level
- MYGN $15.44
- SWI $14.94
- Average True Range (ATR)
- MYGN 0.84
- SWI 0.46
- MACD
- MYGN -0.02
- SWI -0.04
- Stochastic Oscillator
- MYGN 12.37
- SWI 66.21
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About SWI SolarWinds Corporation
SolarWinds Corp is a provider of information technology (IT), and management software. Company offers full-stack observability solutions. The company's business is focused on building products that enable technology professionals and leaders to securely monitor and manage the performance of their IT environments, whether on-premises, in the cloud or in hybrid deployments. The products offered are designed to monitor and manage networks, systems, databases and applications across on-premises, multi-cloud and hybrid IT environments without the need for customization or professional services.